Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT ID: NCT00680186

Last Updated: 2014-05-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 2589 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30

Brief Summary

The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE.

The primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.

Conditions

Thromboembolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Dabigatran etexilate (150mg bid)

Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily

Group Type: EXPERIMENTAL

Dabigatran etexilate

Intervention Type: DRUG

150mg bid

Warfarin (INR 2.0-3.0)

Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0

Group Type: ACTIVE_COMPARATOR

Warfarin

Intervention Type: DRUG

PRN (to maintain a target INR of 2.0-3.0)

Interventions

Warfarin

PRN (to maintain a target INR of 2.0-3.0)

Intervention Type: DRUG

Dabigatran etexilate

150mg bid

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Acute symptomatic uni- or bilateral Deep Vein Thrombosis (DVT) of the leg involving proximal veins, and/or Pulmonary Embolism (PE)
• Male or female, being 18 years of age or older
• Written informed consent for study participation

Exclusion Criteria

• Persistent symptoms of VTE
• PE requiring urgent intervention
• Use of vena cava filter
• Contraindications to anticoagulant therapy
• Allergy to study medications
• Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) > 3x Upper Limit of Normal (ULN) or known liver disease expected to have an impact on survival
• Severe renal impairment
• Patients considered unsuitable for inclusion

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

1160.46.01073 Boehringer Ingelheim Investigational Site

Little Rock, Arkansas, United States

1160.46.01044 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

1160.46.01068 Boehringer Ingelheim Investigational Site

Normal, Illinois, United States

1160.46.01071 Boehringer Ingelheim Investigational Site

Shreveport, Louisiana, United States

1160.46.01060 Boehringer Ingelheim Investigational Site

Stony Brook, New York, United States

1160.46.01061 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

1160.46.01059 Boehringer Ingelheim Investigational Site

Bend, Oregon, United States

1160.46.01063 Boehringer Ingelheim Investigational Site

Corvallis, Oregon, United States

1160.46.01055 Boehringer Ingelheim Investigational Site

Summerville, South Carolina, United States

1160.46.01062 Boehringer Ingelheim Investigational Site

Bellevue, Washington, United States

1160.46.61007 Boehringer Ingelheim Investigational Site

Concord, New South Wales, Australia

1160.46.61003 Boehringer Ingelheim Investigational Site

Box Hill, Victoria, Australia

1160.46.61001 Boehringer Ingelheim Investigational Site

Clayton, Victoria, Australia

1160.46.61006 Boehringer Ingelheim Investigational Site

Windsor, Victoria, Australia

1160.46.61005 Boehringer Ingelheim Investigational Site

Perth, Western Australia, Australia

1160.46.55010 Boehringer Ingelheim Investigational Site

Brasília, , Brazil

1160.46.55007 Boehringer Ingelheim Investigational Site

Campinas, , Brazil

1160.46.55014 Boehringer Ingelheim Investigational Site

Curitiba, , Brazil

1160.46.55017 Boehringer Ingelheim Investigational Site

Curitiba, , Brazil

1160.46.55019 Boehringer Ingelheim Investigational Site

Porto Alegre, , Brazil

1160.46.55021 Boehringer Ingelheim Investigational Site

Recife, , Brazil

1160.46.55016 Boehringer Ingelheim Investigational Site

Rio de Janeiro - RJ, , Brazil

1160.46.55018 Boehringer Ingelheim Investigational Site

São Bernardo do Campo, , Brazil

1160.46.55020 Boehringer Ingelheim Investigational Site

São Paulo, , Brazil

1160.46.35901 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

1160.46.35903 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

1160.46.35906 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

1160.46.35905 Boehringer Ingelheim Investigational Site

Varna, , Bulgaria

1160.46.02006 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

1160.46.02013 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

1160.46.02021 Boehringer Ingelheim Investigational Site

Victoria, British Columbia, Canada

1160.46.02004 Boehringer Ingelheim Investigational Site

Saint John, New Brunswick, Canada

1160.46.02001 Boehringer Ingelheim Investigational Site

Halifax, Nova Scotia, Canada

1160.46.02002 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

1160.46.02005 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

1160.46.02010 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

1160.46.02015 Boehringer Ingelheim Investigational Site

Ottawa, Ontario, Canada

1160.46.02019 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

1160.46.02008 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

1160.46.02009 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

1160.46.02014 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

1160.46.02017 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

1160.46.02020 Boehringer Ingelheim Investigational Site

Québec, Quebec, Canada

1160.46.86001 Boehringer Ingelheim Investigational Site

Beijing, , China

1160.46.86002 Boehringer Ingelheim Investigational Site

Beijing, , China

1160.46.86019 Boehringer Ingelheim Investigational Site

Beijing, , China

1160.46.86014 Boehringer Ingelheim Investigational Site

Guangzhou, , China

1160.46.86015 Boehringer Ingelheim Investigational Site

Guangzhou, , China

1160.46.86016 Boehringer Ingelheim Investigational Site

Hangzhou, , China

1160.46.86003 Boehringer Ingelheim Investigational Site

Shanghai, , China

1160.46.86004 Boehringer Ingelheim Investigational Site

Shanghai, , China

1160.46.86005 Boehringer Ingelheim Investigational Site

Shanghai, , China

1160.46.86011 Boehringer Ingelheim Investigational Site

Shanghai, , China

1160.46.86007 Boehringer Ingelheim Investigational Site

Shenyang, , China

1160.46.86017 Boehringer Ingelheim Investigational Site

Shijiazhuang, , China

1160.46.86018 Boehringer Ingelheim Investigational Site

Shijiazhuang, , China

1160.46.86021 Boehringer Ingelheim Investigational Site

Taiyuan, , China

1160.46.86006 Boehringer Ingelheim Investigational Site

Tianjin, , China

1160.46.86020 Boehringer Ingelheim Investigational Site

Yinchuan, , China

1160.46.42001 Boehringer Ingelheim Investigational Site

Brno, , Czechia

1160.46.42002 Boehringer Ingelheim Investigational Site

Hradec Králové, , Czechia

1160.46.42012 Boehringer Ingelheim Investigational Site

Liberec, , Czechia

1160.46.42018 Boehringer Ingelheim Investigational Site

Litoměřice, , Czechia

1160.46.42015 Boehringer Ingelheim Investigational Site

Nový Jičín, , Czechia

1160.46.42005 Boehringer Ingelheim Investigational Site

Ostrava-Vitkovice, , Czechia

1160.46.42017 Boehringer Ingelheim Investigational Site

Prague, , Czechia

1160.46.42014 Boehringer Ingelheim Investigational Site

Tábor, , Czechia

1160.46.42016 Boehringer Ingelheim Investigational Site

Teplice, , Czechia

1160.46.42010 Boehringer Ingelheim Investigational Site

Ústí nad Labem, , Czechia

1160.46.42007 Boehringer Ingelheim Investigational Site

Zlín, , Czechia

1160.46.45001 Boehringer Ingelheim Investigational Site

Aarhus C, , Denmark

1160.46.45008 Boehringer Ingelheim Investigational Site

Esbjerg, , Denmark

1160.46.45009 Boehringer Ingelheim Investigational Site

Holbæk, , Denmark

1160.46.45004 Boehringer Ingelheim Investigational Site

København NV, , Denmark

1160.46.3301A Boehringer Ingelheim Investigational Site

Brest, , France

1160.46.3301B Boehringer Ingelheim Investigational Site

Brest, , France

1160.46.3315A Boehringer Ingelheim Investigational Site

La Roche-sur-Yon, , France

1160.46.3315B Boehringer Ingelheim Investigational Site

La Roche-sur-Yon, , France

1160.46.3313A Boehringer Ingelheim Investigational Site

Nantes, , France

1160.46.3316A Boehringer Ingelheim Investigational Site

Pessac, , France

1160.46.3316B Boehringer Ingelheim Investigational Site

Pessac, , France

1160.46.3303C Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

1160.46.3303D Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

1160.46.3303E Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

1160.46.3303F Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

1160.46.3303G Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

1160.46.3303H Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

1160.46.3303A Boehringer Ingelheim Investigational Site

Saint-Priest-en-Jarez, , France

1160.46.3303B Boehringer Ingelheim Investigational Site

Saint-Priest-en-Jarez, , France

1160.46.36002 Boehringer Ingelheim Investigational Site

Debrecen, , Hungary

1160.46.36010 Boehringer Ingelheim Investigational Site

Székesfehérvár, , Hungary

1160.46.36011 Boehringer Ingelheim Investigational Site

Szombathely, , Hungary

1160.46.91006 Boehringer Ingelheim Investigational Site

Bangalore, , India

1160.46.91010 Boehringer Ingelheim Investigational Site

Bangalore, , India

1160.46.91002 Boehringer Ingelheim Investigational Site

Chennai, , India

1160.46.91007 Boehringer Ingelheim Investigational Site

Chennai, , India

1160.46.91012 Boehringer Ingelheim Investigational Site

Kolkata, , India

1160.46.91009 Boehringer Ingelheim Investigational Site

Ludhiana, , India

1160.46.91008 Boehringer Ingelheim Investigational Site

Nagpur, , India

1160.46.91005 Boehringer Ingelheim Investigational Site

New Delhi, , India

1160.46.91014 Boehringer Ingelheim Investigational Site

New Delhi, , India

1160.46.91001 Boehringer Ingelheim Investigational Site

Pune, , India

1160.46.91004 Boehringer Ingelheim Investigational Site

Pune, , India

1160.46.91011 Boehringer Ingelheim Investigational Site

Tamil Nadu, , India

1160.46.91013 Boehringer Ingelheim Investigational Site

Vadodara, , India

1160.46.91003 Boehringer Ingelheim Investigational Site

Vadodra, , India

1160.46.97202 Boehringer Ingelheim Investigational Site

Afula, , Israel

1160.46.97207 Boehringer Ingelheim Investigational Site

Ashkelon, , Israel

1160.46.97212 Boehringer Ingelheim Investigational Site

DN Lower Galillee, , Israel

1160.46.97211 Boehringer Ingelheim Investigational Site

Haifa, , Israel

1160.46.97203 Boehringer Ingelheim Investigational Site

Holon, , Israel

1160.46.97205 Boehringer Ingelheim Investigational Site

KfarSaba, , Israel

1160.46.97209 Boehringer Ingelheim Investigational Site

Nazareth, , Israel

1160.46.97206 Boehringer Ingelheim Investigational Site

Petah Tikva, , Israel

1160.46.97210 Boehringer Ingelheim Investigational Site

Tel Aviv, , Israel

1160.46.97204 Boehringer Ingelheim Investigational Site

Tel Hashomer, Ramat Gan, , Israel

1160.46.97201 Boehringer Ingelheim Investigational Site

Ẕerifin, , Israel

1160.46.39011 Boehringer Ingelheim Investigational Site

Catania, , Italy

1160.46.39015 Boehringer Ingelheim Investigational Site

Florence, , Italy

1160.46.39012 Boehringer Ingelheim Investigational Site

Palermo, , Italy

1160.46.39007 Boehringer Ingelheim Investigational Site

Reggio Emilia, , Italy

1160.46.39013 Boehringer Ingelheim Investigational Site

Verona, , Italy

1160.46.39005 Boehringer Ingelheim Investigational Site

Vittorio Veneto (TV), , Italy

1160.46.60001 Boehringer Ingelheim Investigational Site

Kelantan Kota Bahru, , Malaysia

1160.46.60004 Boehringer Ingelheim Investigational Site

Kuala Pahang, , Malaysia

1160.46.60002 Boehringer Ingelheim Investigational Site

Kuala Selangor, , Malaysia

1160.46.60003 Boehringer Ingelheim Investigational Site

Malacca, , Malaysia

1160.46.31010 Boehringer Ingelheim Investigational Site

's-Hertogenbosch, , Netherlands

1160.46.31017 Boehringer Ingelheim Investigational Site

Alkmaar, , Netherlands

1160.46.31001 Boehringer Ingelheim Investigational Site

Amersfoort, , Netherlands

1160.46.31013 Boehringer Ingelheim Investigational Site

Eindhoven, , Netherlands

1160.46.31014 Boehringer Ingelheim Investigational Site

Heerlen, , Netherlands

1160.46.31002 Boehringer Ingelheim Investigational Site

Nieuwegein, , Netherlands

1160.46.31004 Boehringer Ingelheim Investigational Site

Rotterdam, , Netherlands

1160.46.31015 Boehringer Ingelheim Investigational Site

Zwolle, , Netherlands

1160.46.64004 Boehringer Ingelheim Investigational Site

Christchurch, , New Zealand

1160.46.64003 Boehringer Ingelheim Investigational Site

Grafton Auckland, , New Zealand

1160.46.64002 Boehringer Ingelheim Investigational Site

Otahuhu Auckland, , New Zealand

1160.46.64001 Boehringer Ingelheim Investigational Site

Takapuna Auckland, , New Zealand

1160.46.47001 Boehringer Ingelheim Investigational Site

Oslo, , Norway

1160.46.47005 Boehringer Ingelheim Investigational Site

Trondheim, , Norway

1160.46.63005 Boehringer Ingelheim Investigational Site

City of Muntinlupa, , Philippines

1160.46.63001 Boehringer Ingelheim Investigational Site

Manila, , Philippines

1160.46.63003 Boehringer Ingelheim Investigational Site

Quezon City, , Philippines

1160.46.63004 Boehringer Ingelheim Investigational Site

Quezon City, , Philippines

1160.46.48004 Boehringer Ingelheim Investigational Site

Kielce, , Poland

1160.46.48001 Boehringer Ingelheim Investigational Site

Krakow, , Poland

1160.46.48005 Boehringer Ingelheim Investigational Site

Krakow, , Poland

1160.46.48003 Boehringer Ingelheim Investigational Site

Poznan, , Poland

1160.46.48006 Boehringer Ingelheim Investigational Site

Warsaw, , Poland

1160.46.07021 Boehringer Ingelheim Investigational Site

Chelyabinsk, , Russia

1160.46.07016 Boehringer Ingelheim Investigational Site

Krasnodar, , Russia

1160.46.07004 Boehringer Ingelheim Investigational Site

Kursk, , Russia

1160.46.07009 Boehringer Ingelheim Investigational Site

Rostov-on-Don, , Russia

1160.46.07024 Boehringer Ingelheim Investigational Site

Rostov-on-Don, , Russia

1160.46.07014 Boehringer Ingelheim Investigational Site

Ufa, , Russia

1160.46.07005 Boehringer Ingelheim Investigational Site

Yaroslavl, , Russia

1160.46.07006 Boehringer Ingelheim Investigational Site

Yaroslavl, , Russia

1160.46.07007 Boehringer Ingelheim Investigational Site

Yekaterinburg, , Russia

1160.46.65001 Boehringer Ingelheim Investigational Site

Singapore, , Singapore

1160.46.65002 Boehringer Ingelheim Investigational Site

Singapore, , Singapore

1160.46.65003 Boehringer Ingelheim Investigational Site

Singapore, , Singapore

1160.46.42107 Boehringer Ingelheim Investigational Site

Banská Bystrica, , Slovakia

1160.46.42106 Boehringer Ingelheim Investigational Site

Lučenec, , Slovakia

1160.46.42102 Boehringer Ingelheim Investigational Site

Nitra, , Slovakia

1160.46.42103 Boehringer Ingelheim Investigational Site

Nové Zámky, , Slovakia

1160.46.27001 Boehringer Ingelheim Investigational Site

Bryanston, , South Africa

1160.46.27013 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

1160.46.27007 Boehringer Ingelheim Investigational Site

Centurion, , South Africa

1160.46.27014 Boehringer Ingelheim Investigational Site

Kempton Park, , South Africa

1160.46.27015 Boehringer Ingelheim Investigational Site

Krugersdorp, , South Africa

1160.46.27002 Boehringer Ingelheim Investigational Site

Morningside, , South Africa

1160.46.27012 Boehringer Ingelheim Investigational Site

Plumstead, , South Africa

1160.46.27006 Boehringer Ingelheim Investigational Site

Sunninghill, , South Africa

1160.46.82007 Boehringer Ingelheim Investigational Site

Busan, , South Korea

1160.46.82003 Boehringer Ingelheim Investigational Site

Goyang-si, , South Korea

1160.46.82008 Boehringer Ingelheim Investigational Site

Gyeonggi-do, , South Korea

1160.46.82010 Boehringer Ingelheim Investigational Site

Gyeonggi-do, , South Korea

1160.46.82002 Boehringer Ingelheim Investigational Site

Kyunggi-do, , South Korea

1160.46.82004 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

1160.46.82005 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

1160.46.82006 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

1160.46.82009 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

1160.46.34002 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

1160.46.34007 Boehringer Ingelheim Investigational Site

Cartagena. Murcia, , Spain

1160.46.34009 Boehringer Ingelheim Investigational Site

Madrid, , Spain

1160.46.34015 Boehringer Ingelheim Investigational Site

Palma de Mallorca, , Spain

1160.46.34014 Boehringer Ingelheim Investigational Site

Sabadell - Barcelona, , Spain

1160.46.34011 Boehringer Ingelheim Investigational Site

Valencia, , Spain

1160.46.46002 Boehringer Ingelheim Investigational Site

Gothenburg, , Sweden

1160.46.46010 Boehringer Ingelheim Investigational Site

Kristianstad, , Sweden

1160.46.46001 Boehringer Ingelheim Investigational Site

Stockholm, , Sweden

1160.46.46008 Boehringer Ingelheim Investigational Site

Stockholm, , Sweden

1160.46.46003 Boehringer Ingelheim Investigational Site

Uppsala, , Sweden

1160.46.88607 Boehringer Ingelheim Investigational Site

Changhua, , Taiwan

1160.46.88604 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

1160.46.88606 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

1160.46.88608 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

1160.46.88609 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

1160.46.66007 Boehringer Ingelheim Investigational Site

Bangkok, , Thailand

1160.46.66010 Boehringer Ingelheim Investigational Site

Bangkok, , Thailand

1160.46.66001 Boehringer Ingelheim Investigational Site

Khon Kaen, , Thailand

1160.46.66004 Boehringer Ingelheim Investigational Site

Muang Nakhonratchasima, , Thailand

1160.46.66005 Boehringer Ingelheim Investigational Site

Nakhonratchasima, , Thailand

1160.46.66006 Boehringer Ingelheim Investigational Site

Nokorn Nayok, , Thailand

1160.46.66008 Boehringer Ingelheim Investigational Site

Phayathai, , Thailand

1160.46.90003 Boehringer Ingelheim Investigational Site

Ankara, , Turkey (Türkiye)

1160.46.90004 Boehringer Ingelheim Investigational Site

Ankara, , Turkey (Türkiye)

1160.46.90001 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

1160.46.90002 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

1160.46.90007 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

1160.46.90008 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

1160.46.90009 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

1160.46.90010 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

1160.46.38005 Boehringer Ingelheim Investigational Site

Vinnitsa, , Ukraine

1160.46.44005 Boehringer Ingelheim Investigational Site

Headington, Oxford, , United Kingdom

1160.46.44011 Boehringer Ingelheim Investigational Site

London, , United Kingdom

1160.46.44006 Boehringer Ingelheim Investigational Site

Newcastle upon Tyne, , United Kingdom

1160.46.44013 Boehringer Ingelheim Investigational Site

Plymouth, , United Kingdom

1160.46.44012 Boehringer Ingelheim Investigational Site

Sheffield, , United Kingdom

Countries

United States; Australia; Brazil; Bulgaria; Canada; China; Czechia; Denmark; France; Hungary; India; Israel; Italy; Malaysia; Netherlands; New Zealand; Norway; Philippines; Poland; Russia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); Ukraine; United Kingdom

References

Goldhaber SZ, Eriksson H, Kakkar A, Schellong S, Feuring M, Fraessdorf M, Kreuzer J, Schueler E, Schulman S. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER(R), RE-COVER II, and RE-MEDY. Vasc Med. 2016 Dec;21(6):506-514. doi: 10.1177/1358863X16668588. Epub 2016 Nov 1.

Reference Type: DERIVED

PMID: 27807306 (View on PubMed)

Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16.

Reference Type: DERIVED

PMID: 24344086 (View on PubMed)

Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.

Reference Type: DERIVED

PMID: 24081972 (View on PubMed)

Other Identifiers

2007-002631-86

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1160.46

Identifier Type: -

Identifier Source: org_study_id